Cargando…
Engineered MED12 mutations drive leiomyoma-like transcriptional and metabolic programs by altering the 3D genome compartmentalization
Nearly 70% of Uterine fibroid (UF) tumors are driven by recurrent MED12 hotspot mutations. Unfortunately, no cellular models could be generated because the mutant cells have lower fitness in 2D culture conditions. To address this, we employ CRISPR to precisely engineer MED12 Gly44 mutations in UF-re...
Autores principales: | Buyukcelebi, Kadir, Chen, Xintong, Abdula, Fatih, Elkafas, Hoda, Duval, Alexander James, Ozturk, Harun, Seker-Polat, Fidan, Jin, Qiushi, Yin, Ping, Feng, Yue, Bulun, Serdar E., Wei, Jian Jun, Yue, Feng, Adli, Mazhar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333368/ https://www.ncbi.nlm.nih.gov/pubmed/37429859 http://dx.doi.org/10.1038/s41467-023-39684-y |
Ejemplares similares
-
Engineered MED12 mutations drive uterine fibroid-like transcriptional and metabolic programs by altering the 3D genome compartmentalization
por: Buyukcelebi, Kadir, et al.
Publicado: (2023) -
Tryptophan 2,3-Dioxygenase-2 in Uterine Leiomyoma: Dysregulation by MED12 Mutation Status
por: Hutchinson, Anne P., et al.
Publicado: (2022) -
Progesterone receptor integrates the effects of mutated MED12 and altered DNA methylation to stimulate RANKL expression and stem cell proliferation in uterine leiomyoma
por: Liu, Shimeng, et al.
Publicado: (2018) -
MED12 mutation activates the tryptophan/kynurenine/AHR pathway to promote growth of uterine leiomyomas
por: Zuberi, Azna, et al.
Publicado: (2023) -
THU625 Med12 Mutation Activates Tryptophan-Kynurenine-ahr Pathway To Promote Growth Of Uterine Leiomyoma
por: Zuberi, Azna, et al.
Publicado: (2023)